Cytosorbents (CTSO) Other Accumulated Expenses (2018 - 2026)

Cytosorbents (CTSO) has reported Other Accumulated Expenses for 9 consecutive years, with $558000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Accumulated Expenses fell 42.18% year-over-year to $558000.0; the trailing twelve-month figure through Jun 2026 stood at $558000.0 (down 42.18% YoY), and the FY2025 full-year result was $271000.0, down 1.45% from the prior year.
• Other Accumulated Expenses climbed to $558000.0 in Q2 2026 per CTSO's latest filing, from $268000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $991545.0 in Q4 2023 and bottomed at $268000.0 in Q1 2026.
• Historically, Other Accumulated Expenses has averaged $555540.9 across 5 years, with a median of $558000.0 in 2026.
• The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses soared 67.38% in 2023, then tumbled 72.27% in 2024.
• Over 5 years, Other Accumulated Expenses stood at $592398.0 in 2022, then jumped by 67.38% to $991545.0 in 2023, then sank by 72.27% to $275000.0 in 2024, then dropped by 1.45% to $271000.0 in 2025, then surged by 105.9% to $558000.0 in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $558000.0, $268000.0, and $271000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.